Published in Cancer Res on January 19, 2010
TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell (2011) 2.49
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Claudins and the modulation of tight junction permeability. Physiol Rev (2013) 2.05
Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem (2011) 1.70
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature (2015) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol (2012) 1.42
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adh Migr (2012) 1.34
Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Exp Pathol (2011) 1.34
TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol (2015) 1.23
Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One (2012) 1.18
Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene (2012) 1.14
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics (2010) 1.05
Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. Oncogene (2013) 1.03
Epigenetic reprogramming: is deamination key to active DNA demethylation? Reproduction (2011) 1.03
Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest (2013) 1.03
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics (2014) 0.99
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 0.96
An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics (2012) 0.92
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer (2014) 0.91
Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res (2012) 0.89
The dual role of Smad7 in the control of cancer growth and metastasis. Int J Mol Sci (2013) 0.88
Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun (2014) 0.87
Expression changes of cell-cell adhesion-related genes in colorectal tumors. Oncol Lett (2015) 0.84
Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res (2015) 0.83
Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways. Cell Stress Chaperones (2015) 0.83
Reprogramming during epithelial to mesenchymal transition under the control of TGFβ. Cell Adh Migr (2014) 0.83
Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition. J Clin Med (2016) 0.82
Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. BMC Genomics (2014) 0.82
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Oncotarget (2016) 0.82
Multiscale modelling of solid tumour growth: the effect of collagen micromechanics. Biomech Model Mechanobiol (2015) 0.81
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. Nucleic Acids Res (2014) 0.81
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med (2016) 0.80
Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer (2016) 0.80
OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling. Am J Cancer Res (2015) 0.80
Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia. Oncotarget (2014) 0.79
Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol Life Sci (2016) 0.79
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med (2016) 0.77
TGF-β1 epigenetically modifies Thy-1 expression in primary lung fibroblasts. Am J Physiol Cell Physiol (2015) 0.77
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer. ISRN Dermatol (2013) 0.77
MicroRNA expression analysis of mammospheres cultured from human breast cancers. J Cancer Res Clin Oncol (2012) 0.77
Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells. Mol Cancer Res (2015) 0.76
Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy. J Control Release (2017) 0.76
Pathway bridge based multiobjective optimization approach for lurking pathway prediction. Biomed Res Int (2014) 0.75
Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma. Oncotarget (2016) 0.75
Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats. PLoS One (2013) 0.75
Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome. BMC Cancer (2015) 0.75
SMAD2 Inactivation Inhibits CLDN6 Methylation to Suppress Migration and Invasion of Breast Cancer Cells. Int J Mol Sci (2017) 0.75
LGR5 promotes hepatocellular carcinoma metastasis through inducting epithelial-mesenchymal transition. Oncotarget (2017) 0.75
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Cancer metastasis: building a framework. Cell (2006) 19.67
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet (2005) 15.37
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Smad transcription factors. Genes Dev (2005) 13.43
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Making sense of latent TGFbeta activation. J Cell Sci (2003) 8.90
The colorful history of active DNA demethylation. Cell (2008) 8.50
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell (1997) 6.34
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev (1996) 5.71
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol (1998) 4.44
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A (1995) 4.28
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene (2008) 3.63
Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52
DNA demethylation by DNA repair. Trends Genet (2009) 3.49
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet (2002) 3.25
TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem (1997) 3.03
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
DNA methylation in breast and colorectal cancers. Mod Pathol (2007) 2.88
Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis (2008) 2.86
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res (2006) 2.64
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem (2002) 1.89
Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2003) 1.59
Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A (1998) 1.55
hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells. Cancer Biol Ther (2009) 1.49
Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat (2000) 1.39
Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2004) 1.38
The role for NES1 serine protease as a novel tumor suppressor. Cancer Res (1998) 1.23
Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci (2003) 3.05
Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am J Physiol Endocrinol Metab (2006) 3.03
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet (2006) 2.53
Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet (2005) 2.34
Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res (2011) 2.19
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer (2004) 1.78
African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark (2007) 1.76
A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. Am J Respir Crit Care Med (2013) 1.73
Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res (Phila) (2011) 1.61
High-efficiency and heritable gene targeting in mouse by transcription activator-like effector nucleases. Nucleic Acids Res (2013) 1.61
the need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis. Cancer Inform (2005) 1.58
Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol (2008) 1.54
hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells. Cancer Biol Ther (2009) 1.49
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res (2011) 1.28
Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res (2005) 1.26
DNA polymerase V allows bypass of toxic guanine oxidation products in vivo. J Biol Chem (2007) 1.25
Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol (2010) 1.24
The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncol (2013) 1.22
DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res (2011) 1.21
Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr Opin Oncol (2002) 1.21
Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol (2009) 1.20
Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. Breast J (2012) 1.19
Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples. Nucleic Acids Res (2004) 1.18
Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res (2009) 1.13
The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res (2013) 1.12
Replication licensing promotes cyclin D1 expression and G1 progression in untransformed human cells. Cell Cycle (2009) 1.11
High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer (2005) 1.09
Hypomethylation of the serotonin receptor type-2A Gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.06
Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics (2005) 1.03
Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer (2009) 1.03
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer (2003) 1.03
Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autism. PLoS One (2013) 1.02
Regulation of mast cell survival and function by tuberous sclerosis complex 1. Blood (2012) 1.01
Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer (2010) 1.00
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev (2003) 0.99
Receptor signaling in immune cell development and function. Immunol Res (2011) 0.98
Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am J Respir Cell Mol Biol (2005) 0.97
Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One (2012) 0.94
Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol (2008) 0.93
Lgr4-mediated Wnt/β-catenin signaling in peritubular myoid cells is essential for spermatogenesis. Development (2013) 0.92
Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax (2013) 0.91
miRNAs are stable in colorectal cancer archival tissue blocks. Front Biosci (Elite Ed) (2012) 0.91
Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res (2005) 0.91
Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One (2012) 0.90
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res (2012) 0.90
Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther (2007) 0.90
Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer. J Hematol Oncol (2011) 0.89
Is the elapsed time following the placement of a ventriculoperitoneal shunt catheter an individual risk factor for shunt fractures? Pediatr Neurosurg (2013) 0.89
Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer (2002) 0.89
Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark (2005) 0.88
Integrin signaling in mammary epithelial cells and breast cancer. ISRN Oncol (2012) 0.88
Lgr4 gene deficiency increases susceptibility and severity of dextran sodium sulfate-induced inflammatory bowel disease in mice. J Biol Chem (2013) 0.87
Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci (2012) 0.86
Characterization of the mid-foregut transcriptome identifies genes regulated during lung bud induction. Gene Expr Patterns (2007) 0.86
The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark (2010) 0.86
Transcriptional responses of neonatal mouse lung to hyperoxia by Nrf2 status. Cytokine (2013) 0.85
Methionine inhibits cellular growth dependent on the p53 status of cells. Am J Surg (2007) 0.85
Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiol Genomics (2005) 0.85
Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display. Cancer Res (2004) 0.85
Comparison of the predictive qualities of three prognostic models of colorectal cancer. Front Biosci (Elite Ed) (2010) 0.84
Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics (2008) 0.83
Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog (2012) 0.82
hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. Cancer Biol Ther (2009) 0.82
Understanding racial differences in colorectal cancer aids in individualized medicine. Future Oncol (2007) 0.81
Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol (2006) 0.81
Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma. Front Biosci (2008) 0.81
Progress in asymmetric biomimetic transamination of carbonyl compounds. Chem Soc Rev (2015) 0.80
Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med (2006) 0.80
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer (2014) 0.80
HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis. Mol Cell Pharmacol (2009) 0.79
p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior. J Histochem Cytochem (2007) 0.79
Translational pathology of neoplasia. Cancer Biomark (2010) 0.79
Development of combination tapered fiber-optic biosensor dip probe for quantitative estimation of interleukin-6 in serum samples. J Biomed Opt (2011) 0.79
Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers. Chest (2003) 0.79
[Effect of gallnut extract on nasopharyngeal carcinoma 5-8F cells and its mechanism]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2012) 0.78